FDA Approves Brodalumab for Psoriasis
FDA approved Valeant’s brodalumab with a boxed warning for suicidal ideation.
On Feb. 15, 2017, FDA approved Valeant’s Siliq (brodalumab) for the treatment of moderate-to-severe plaque psoriasis. The monoclonal antibody (mAb) works by binding to the IL-17 receptor and is meant for patients who are candidates for systemic therapy or phototherapy, and have failed to respond or stopped responding to other systemic therapies.
Brodalumab does have some notable adverse events, FDA said in a statement. During clinical trials, there were instances of patients demonstrating suicidal ideation. FDA noted, however, that a casual association between brodalumab and an increased risk of suicidal behavior or ideation has not been established. Because of this risk, the drug will come with a boxed warning and will only be available under a Risk Evaluation and Mitigation Strategy (REMS) program.
In 2015, Amgen dropped out of co-developing the mAb with AstraZeneca when it became clear patients were demonstrating thoughts of suicide. In September 2015, Valeant took over the commercialization and development of the mAb.
Source: FDA
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
